DOI:
10.1055/s-00033990
TH Open
LinksClose Window
References
Del Paggio JC, Tannock IF.
The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis.
Lancet Oncol 2019;
20 (08) 1065-1069
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.